Multiple presentation of Scfv800E6 on silica nanospheres enhances targeting efficiency toward HER-2 receptor in breast cancer cells

Bioconjug Chem. 2011 Nov 16;22(11):2296-303. doi: 10.1021/bc200352x. Epub 2011 Oct 31.

Abstract

Spherical silica nanoparticles (SNP) have been synthesized and functionalized with anti-HER-2 scFv800E6 antibody by both localized histidine-tag recognition, leading to an oriented protein ligation, and glutaraldehyde cross-linking, exploiting a statistical reactivity of lysine amine groups in the primary sequence of the molecule. The targeting efficiency of nanocomplexes in comparison with free scFv was evaluated by flow cytometry using a HER-2 antigen-positive MCF-7 breast cancer cell line, exhibiting a 4-fold increase in scFv binding efficacy, close to the affinity of intact anti-HER-2 monoclonal antibody, which suggests the effectiveness of presenting multiple scFv molecules on nanoparticles in improving antigen recognition. Unexpectedly, the conjugation method did not affect the binding efficacy of scFv, suggesting a structural role of lysines in the scFv molecule. Confocal laser scanning microscopy confirmed the binding of nanocomplexes to HER-2 and also provided evidence of their localization at the cell surface.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Animals
  • Breast Neoplasms / drug therapy
  • Breast Neoplasms / metabolism*
  • Cell Line, Tumor
  • Female
  • Humans
  • Mice
  • Models, Molecular
  • Molecular Structure
  • Nanospheres / chemistry*
  • Nanospheres / ultrastructure
  • Receptor, ErbB-2 / metabolism*
  • Silicon Dioxide / chemistry*
  • Single-Chain Antibodies / chemistry*
  • Single-Chain Antibodies / genetics
  • Single-Chain Antibodies / metabolism*
  • Single-Chain Antibodies / therapeutic use

Substances

  • Single-Chain Antibodies
  • Silicon Dioxide
  • Receptor, ErbB-2